Navigation Links
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Date:12/6/2010

EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- The Novartis Pharmaceutical Corporation ("Novartis") oral investigational drug LBH589 (panobinostat) demonstrated substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients who had relapsed or had become refractory after an autologous stem cell transplant, according to new data from a Phase II clinical trial presented today(1).

In this pivotal single-arm study, one of the largest ever conducted in this patient population, 82% (n=106) of patients, most in their fifth line of therapy or beyond, achieved disease control (defined as stable disease or better) and 74% (n=96) achieved tumor reduction at a median follow-up of 9.6 months, demonstrating the sustained anticancer activity of LBH589. Partial and complete responses to treatment, the primary endpoint, were observed in 27% of patients (n=35), with a median duration of response of 6.9 months and a median progression-free survival measured at 10.5 months among those 35 patients(1).

These data were presented today at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Florida. Worldwide regulatory filings are planned based on the study results.

Currently, up to 35% of patients with Hodgkin lymphoma relapse or become refractory after initial treatment, which typically involves at least two regimens of combination chemotherapy along with high-dose chemotherapy and stem cell transplant(2). Most patients enrolled in this study had received nearly all of the chemotherapy drugs known to be active in this disease, and 79% had failed an additional round of chemotherapy after a stem cell transplant. In addition, 10% of patients had also received prior allogeneic stem cell transplantations (stem cells from another person) in addition to an autologous transplant (stem cells from the patient). Palliative care is currently the only option remaining for these patients(3,4). '/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 ... they have added 14 new vendors so far ... Creekridge,s newest vendors are from both ... mid-size domestic organizations to large, well-known multi-national companies. ... Creekridge,s diversified suite of financing products including: standard ...
(Date:7/23/2014)... , July 23, 2014  Mezzion Pharma Co. ... to evaluate the use of udenafil to treat adolescents ... ventricle heart defects. The clinical program will follow protocols ... the Pediatric Heart Network (PHN), a multi-center clinical research ... Institute (NHLBI) of the National Institutes of Health (NIH). ...
(Date:7/23/2014)... , July 23, 2014  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... investigational new drug application ("IND") with respect to ... also announced today that it has received an ... Abuse ("NIDA"), part of the National Institutes of ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
... Orthopedic Group, Inc. (NYSE: HGR ) announced that it continues ... Prosthetics of Texas , Nebraska Orthotic and Prosthetic Services, and Spectrum ... with annual revenues of $14.0 million . , ... "These companies are leaders in their communities ...
... June 22 Draeger Medical Canada, Inc. today announced ... System (AIMS) for the Capital District Health Authority and IWK Health Centre ... , , ... of the most comprehensive information technology solution for the safe delivery and ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Three Acquisitions With Annual Revenues of $14.0 Million 2Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System 2Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System 3
(Date:7/23/2014)... 23, 2014 Four hospitals affiliated with ... in the latest ranking of the country’s best hospitals ... Released online today and slated for publication in August, ... General Hospital (AGH), Forbes Hospital, Saint Vincent Hospital and ... multiple clinical specialties. , “There is no ...
(Date:7/23/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) --,Jealousy may not ... showing dogs can get downright possessive when it comes ... owners showed affection toward what was actually a stuffed ... snapping or pushing the stuffed dog aside, report researchers ... This jealous streak only surfaced when owners were attending ...
(Date:7/23/2014)... In a massive effort to catalog the ... at Dana-Farber Cancer Institute, have identified four subtypes ... molecular abnormalities. They say the new classification promises ... for the third-leading cancer killer worldwide. , In ... The Cancer Genome Atlas Research Network said they ...
(Date:7/23/2014)... Texas Physical Therapy Specialists (TexPTS) is ... Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown clinics ... Orthopaedic Certified Specialist (OCS) or Sports ... DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason Brown, ... Leech, PT, DPT, OCS, and Mary Grimberg, PT, DPT, ...
(Date:7/23/2014)... 2014 A therapy combining salmon fibrin injections into ... into the brain restored voluntary motor function impaired by ... Center have found. , In a study on rodents, ... turning back the developmental clock in a molecular pathway ... and providing a scaffold so that neuronal axons at ...
Breaking Medicine News(10 mins):Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3Health News:Dogs Can Get Jealous, Too 2Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2
... it time for all community-based doctors to turn to e-prescribing ... According to Rainu Kaushal and colleagues from the Weill Cornell ... prescribing errors up to seven-fold. Their study of ... in the Journal of General Internal Medicine , published ...
... ... renowned publication, The Leading Physicians of the World. Dr. Sood will be representing the ... dermatologists from all over the globe. , ... New York, NY (PRWEB) February 22, 2010 -- As owner of Harper Dermatology ...
... ... ... ... ...
... ... ... ... ...
... proven to enhance bone density and reduce fracture incidence ... increase risk of atypical fractures of the femur when ... research presented today at the 2010 Annual Meeting of ... Bisphosphonates are designed to slow or stop the ...
... , ... best selling author David S. Linthicum kicks off the Webinar series with Best Practices in ... ... of the Leveraging Cloud Computing Within the Modern Data Center webinar series. These media ...
Cached Medicine News:Health News:Physicians click their way to better prescriptions 2Health News:Neuro Drinks Provide Sparkling Refreshment on a Star-Studded Evening at the 18th Annual Academy Awards(R) Viewing Party Hosted by the Elton John AIDS Foundation 2Health News:Neuro Drinks Provide Sparkling Refreshment on a Star-Studded Evening at the 18th Annual Academy Awards(R) Viewing Party Hosted by the Elton John AIDS Foundation 3Health News:Neuro Drinks Provide Sparkling Refreshment on a Star-Studded Evening at the 18th Annual Academy Awards(R) Viewing Party Hosted by the Elton John AIDS Foundation 4Health News:Neuro Drinks Provide Sparkling Refreshment on a Star-Studded Evening at the 18th Annual Academy Awards(R) Viewing Party Hosted by the Elton John AIDS Foundation 5Health News:Kimberly-Clark Introduces Kleenex Hand Towels 2Health News:Kimberly-Clark Introduces Kleenex Hand Towels 3Health News:Kimberly-Clark Introduces Kleenex Hand Towels 4Health News:Kimberly-Clark Introduces Kleenex Hand Towels 5Health News:Kimberly-Clark Introduces Kleenex Hand Towels 6Health News:Quantity vs. quality: Long-term use of bone-building osteoporosis drugs 2Health News:Quantity vs. quality: Long-term use of bone-building osteoporosis drugs 3Health News:Bick Group Launches Leveraging Cloud Computing Within the Modern Data Center Webinar Series 2
... achieves a secure clot, targeted to the ... hemostasis is needed, when control of bleeding ... and cautery, is ineffective or impractical., CROSSEAL* ... of human Biologically Active Component (BAC) and ...
Mastisol Liquid Adhesive is a clear, non-irritating, and non-water-soluble liquid adhesive that secures the most difficult dressings for an extended period of time. Mastisol is 7 to 10 times stickier...
... Indermil® tissue adhesive is indicated for ... laparoscopic incisions, and trauma-induced lacerations in areas ... thoroughly-cleansed, and have easily approximated skin edges. ... tissue adhesive may act as a barrier ...
The first Ethyl-2-Cyanoacrylate tissue adhesive in a tube that is more economical than sutures!...
Medicine Products: